Clinical Trial Update: A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting [Phase 2]

View source ↗

Summary

Phase II trial investigating cabozantinib as first-line treatment for radioiodine-refractory differentiated thyroid carcinoma (DTC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Poorly Differentiated Thyroid Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Differentiated Thyroid Cancer (DTC), Poorly Differentiated Thyroid Cancer | Phase 2 | Status: UNKNOWN